Search Results - "Choy, Gavin"

The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer by Fang, Fang, Munck, Joanne, Tang, Jessica, Taverna, Pietro, Wang, Yinu, Miller, David F B, Pilrose, Jay, Choy, Gavin, Azab, Mohammad, Pawelczak, Katherine S, VanderVere-Carozza, Pamela, Wagner, Michael, Lyons, John, Matei, Daniela, Turchi, John J, Nephew, Kenneth P

“…To investigate SGI-110 as a "chemosensitizer" in ovarian cancer and to assess its effects on tumor suppressor genes (TSG) and chemoresponsiveness-associated…”
Get full text

733 Phase 1 study of ultra-high concentration nitric oxide ablation in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies by Meirovitz, Amichay, Greenberg, David, Avniel, Amir, Choy, Gavin, Monson, Jedidiah

“…BackgroundTumor ablation is a minimally invasive technique commonly used to treat solid tumors in the liver, kidney, bone and lung and is based on thermal and…”
Get full text

Abstract 2096: Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models by Shih, Joe, Zhong, Boyu, Shi, Hepeng, Xue, David, Choy, Gavin S., Redkar, Sanjeev

“…Background: cMET is a receptor tyrosine kinase that is located on the cell surface and is activated by the binding of its ligand, hepatocyte growth factor…”
Get full text

Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients by Schiff, Eugene R., Lai, Ching‐Lung, Hadziyannis, Stefanos, Neuhaus, Peter, Terrault, Norah, Colombo, Massimo, Tillmann, Hans L., Samuel, Didier, Zeuzem, Stefan, Lilly, Leslie, Rendina, Maria, Villeneuve, Jean‐Pierre, Lama, Nicole, James, Craig, Wulfsohn, Michael S., Namini, Hamid, Westland, Christopher, Xiong, Shelly, Choy, Gavin S., Van Doren, Sally, Fry, John, Brosgart, Carol L.

“…Three‐hundred and twenty‐four patients were enrolled in an open‐label, multicenter, international study in which pre‐ and post‐liver transplantation (LT)…”
Get full text

A phase 1, multi-center, safety, feasibility, and preliminary efficacy study evaluating a single dose of UNO101 in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies by Dirbas, Frederick M., Meirovitz, Amichay, Greenberg, David, Dekel, Edith, Choy, Gavin S., Monson, Jedidiah

“…TPS2686 Background: Tumor ablation is a minimally invasive technique commonly used to treat solid tumors in the liver, kidney, bone, and lung and is usually…”
Get full text

The Benefits of In-Home Pharmacy Evaluation for Older Persons by Der, Elaine Hsia, Rubenstein, Laurence Z., Choy, Gavin S.

“…OBJECTIVE: To assess the potential benefit of a pharmacist performing in‐home medication evaluations on frail older people. DESIGN: Prospective analysis with…”
Get full text

Abstract 2205: CBT-102, an oral small molecule multi-kinase inhibitor, demonstrates favorable CSF-1R activity, offering means of controlling tumor associated macrophages by Liu, Elaine, Yang, Lan, Choy, Gavin, Zhang, Xiaoling, Pearce, Tillman, Reddy, Mamatha, Redkar, Sanjeev, Shi, Qian

“…Background: The role of the tumor microenvironment (TME) in fostering the development of malignancies is prompting the pursuit of anticancer therapies that…”
Get full text

Abstract 3945: CBT-102, an oral multi-kinase small molecule, demonstrates favorable activity in human hepatocellular carcinoma animal models and cardiac safety in rabbit Purkinje and beagle dogs compared to sorafenib by Kanekal, Sarath, Zhang, Xiquan, Song, Yanrui, Wenmiao, Tan, Zhang, Juan, Zhang, Deyi, Li, Henry, Reddy, Mamatha, Choy, Gavin, Redkar, Sanjeev

“…Background: Cancer is a complex disease involving disruption of more than one receptor or signaling pathway. Inhibiting multiple oncogenic targets have been…”
Get full text

Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma by Zhou, Qing, Nian, Weihong, Sun, Ziyong, Qiu, Junzhuan, Wang, Zhun, Choy, Gavin, Redkar, Sanjeev

“…Abstract only 108 Background: CBT-501 (Genolimzumab, GB-226) is a novel humanized mAb (IgG4k) against human Programmed Death-1 (PD-1). CBT-501 demonstrated…”
Get full text

A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors by Voskoboynik, Mark, Richardson, Gary Edward, Mileshkin, Linda R., McNeil, Catriona M., Horvath, Lisa, Benedetti, Fabio M., Choy, Gavin S., Sankar, Neil, McCurry, Shelly, Zhang, Xiaoling, Gao, Min, Shah, Ajit K., Millward, Michael

“…Abstract only e15125 Background: APL-501 is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1). APL-501 is being evaluated in patients…”
Get full text

An observational study evaluating the expression of HER2 (1+, 2+, and 3+) with HLA A2/A3+ in gastric adenocarcinoma patients by Patnaik, Ashis, Parvatini, Shyam, Sachdeva, Shalabh, Choy, Gavin S., Sharma, Akhilesh, Jagannath, Palepu

“…Abstract only 18 Background: Gastric cancer remains a major health issue and results in 800,000 annual deaths worldwide. Despite approximately 50% of the…”
Get full text

Effect of novel peptide vaccines on secondary recurrences and survivorship by Valentine, Marye Ellen, Chance, Lacey, Gompper, Peter Todd, Choy, Gavin S.

“…Abstract only e274 Background: According to the NCI Office of Cancer Survivorship, in 2014, it is estimated there are 14.5 million cancer survivors in the US…”
Get full text

Analytical validation of Bond Oracle HER2 IHC system for identifying low to intermediate HER2-expressing breast cancer in NeuVax PRESENT phase III clinical trial by Jain, Amit K, Kumar, Sonia, Choy, Gavin S., Hollemon, Desiree, Mittendorf, Elizabeth Ann

“…Abstract only…”
Get full text

Abstract 3435: GTB-5550 (cam16-IL15-camB7H3) trispecific killer engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas by Khaw, Melissa, Davis, Zachary, Zorko, Nicholas, Berk, Greg, Choy, Gavin, MacMillan, Margaret, Felices, Martin, Miller, Jeffrey S.

“…Worldwide, Head and Neck Squamous Cell Carcinomas (HNSCC) account for about 900,000 cases and 400,000 deaths. In some settings, like Fanconi anemia (FA),…”
Get full text

Abstract A200: CBT-502 (TQB2450), a novel anti-PD-L1 antibody, demonstrates favorable activity in MC-38/H-11 murine colon and A375 human melanoma animal models by Wei, Zhao, Yang, Ling, Li, Yingchun, Lu, Jiansheng, Zhang, Xiquan, Tian, Xin, Zha, Jiping, Sun, Ziyong, Qiu, Junzhuan, Wang, Zhun, Reddy, Mamatha, Choy, Gavin S., Redkar, Sanjeev

“…Background: CBT-502 (TQB2450) is a novel humanized IgG1 antibody against programmed cell death-ligand 1(PD-L1) developed by CBT Pharmaceuticals, Inc. CBT-502…”
Get full text

Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors by Mita, Monica, Gordon, Michael, Rosen, Lee, Kapoor, Nirmal, Choy, Gavin, Redkar, Sanjeev, Taverna, Pietro, Oganesian, Aram, Sahai, Amarpal, Azab, Mohammad, Bristow, Robert, Tolcher, Anthony W.

“…Purpose Amuvatinib is an oral multi-kinase inhibitor that suppresses RAD51, inhibits mutant c-KIT and platelet-derived growth factor receptor alpha, and has…”
Get full text

Abstract 2317: SGI-110 alters ovarian cancer stem cells to prevent recurrent and chemoresistant ovarian cancer by Wang, Yinu, Cardenas, Horacio, Fang, Fang, Condello, Salvatore, Taverna, Pietro, Choy, Gavin, Azab, Mohammad, Nephew, Kenneth, Matei, Daniela

“…Ovarian cancer stem cells (OCSCs) are associated with drug resistance and tumor relapse. Epigenetic aberrations, especially DNA methylation, result in…”
Get full text

A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors by Tibes, Raoul, Fine, Gil, Choy, Gavin, Redkar, Sanjeev, Taverna, Pietro, Oganesian, Aram, Sahai, Amarpal, Azab, Mohammad, Tolcher, Anthony W.

“…Purpose Amuvatinib is a novel orally administered tyrosine kinase inhibitor with in vitro pharmacological activity against mutant KIT, platelet-derived growth…”
Get full text

Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis by Troung, Phu V., Saltzman, Marc, Bessudo, Alberto, Jawien, William, Lyons, Roger M., Berenzon, Dmitriy, Mena, Raul, Wingate-Pearse, Nasiema, Barriere, Olivier, Beeson, Hali E., Glidden, Paul F., Choy, Gavin S., Verstovsek, Srdan

“…Introduction: Agrylin® (United States) and Xagrid® (European Union) are immediate release (IR) preparations of anagrelide hydrochloride that block…”
Get full text

Abstract P2-15-02: HER2 discordant results in local vs. central testing in the phase 3 nelipepimut-S trial and implementation of Leica Bond Oracle HER2 Immunohistochemistry (IHC) System for low and intermediate levels (1+, 2+) of HER2 protein expression as a companion diagn by Melisko, Michelle, Mittendorf, Elizabeth A, Safina, Sufia, Schenker, Michael, Brunt, Murray A, Litwiniuk, Maria, Mackey, John, Petrakova, Katarina, Alieva, Svitiana, Chance, Lacey, Choy, Gavin S, Ahn, Mark, Hamm, Adamm, Kumar, Sonia, Rugo, Hope S

“…Background : The distinction between HER2-positive (IHC 3+ or 2+ with FISH ratio >/= 2) and not overexpressing HER2 has been the focus of many diagnostic tests…”
Get full text